Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes

Archives of Toxicology

Volumn 75, Issue 7, 2001, Pages 425-438

  Haskins, Jeffrey R ^a   Rowse, Paul ^a   Rahbari, Ramin ^a   De la Iglesia, Felix A ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Comparative toxicity; In vitro; Liver; Peripheral leukocytes; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATE; DRUG METABOLITE; PIOGLITAZONE; ROSIGLITAZONE; TOCOPHEROL; TROGLITAZONE;

ANIMAL CELL; ARTICLE; ASSAY; BLOOD; CALCIUM TRANSPORT; CHROMATIN CONDENSATION; CONTROLLED STUDY; CYTOPLASM; DIABETES MELLITUS; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; INSULIN RESISTANCE; LEUKOCYTE; LIVER CELL; LIVER DYSFUNCTION; MEMBRANE PERMEABILITY; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FEMALE; FLOW CYTOMETRY; HEPATOCYTES; HUMANS; LEUKOCYTES; MICROSCOPY, FLUORESCENCE; RATS; RATS, WISTAR; THIAZOLES; TIME FACTORS;

ANIMALIA; RODENTIA;

EID: 0034802960     PISSN: 03405761     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002040100251     Document Type: Article

References (55)

1. The diabetic liver. Cytochemical, ultrastructural, and enzymatic changes
2. Troglitazone induces expression of PPARγ in liver
3. Troglitazone inhibits expression of the phosphoenolpyruvate carboxykinase gene by an insulin-independent mechanism
4. Chronic toxicity study of the antidiabetic troglitazone in Wistar rats
5. Morphofunctional aspects of the hepatic architecture: Functional and subcellular correlates
6. Hepatocytes from newborn and weanling rats in monolayer culture: Isolation by perfusion, fibronectin-mediated adhesion, spreading, and functional activities
7. Toxicity of troglitazone in cultures rat hepatocytes
8. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study
9. Hepatic failure in a patient taking rosiglitazone
10. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats
11. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone
12. Ex vivo functional assessment of mitochondrial transmembrane potential from lean and diabetic Zucker rats with or without troglitazone
13. Subchronic toxicity of the antidiabetic troglitazone in Wistar rats
14. Carcinogenicity study of the antidiabetic troglitazone in Wistar rats
15. Induction of plasminogen activator inhibitor-1 (PAI-1) gene expression in adipocytes by thiazolidinediones
16. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM
17. Unraveling the mechanism of action of thiazolidinediones
18. Rosiglitazone (BRL-49653)
19. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission
20. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs
21. Insulin resistance: Site of the primary defect or how the current and the emerging therapies work
22. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures
23. New therapeutic agents for the treatment of NIDDM
24. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ)
25. The mitochondrial permeability transition in cell death: A common mechanism in necrosis, apoptosis and autophagy
26. Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death
27. Steroid sulphatase deficiency: Identification of heterozygotes using hydrolysis of dehydroepiandrosterone sulphate by peripheral leucocytes
28. Subchronic toxicity of the antidiabetic troglitazone in B6C3F1 mice
29. Carcinogenicity study of the antidiabetic troglitazone in B6C3F1 mice
30. Functional and subcellular organelle changes in isolated rat and human hepatocytes induced by tetrahydroaminoacridine
31. Diabetogenes; which cause type II diabetes mellitus
32. Troglitazone-induced hepatic failure leading to liver transplantation. A case report
33. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
34. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat
35. Insulin resistance in man
36. Pharmacokinetics of troglitazone, a PPAR-γ agonist, in patients with hepatic insufficiency
37. Acridine-induced subcellular and functional changes in isolated human hepatocytes in vitro
38. Monitoring simultaneous subcellular events in vitro by means of coherent multiprobe fluorescence
39. Troglitazone increases cytochrome P-450 3 A protein and activity in primary cultures of human hepatocytes
40. Mechanisms by which thiazolidinediones enhance insulin action
41. 52-Week oral toxicity study of troglitazone in cynomolgus monkeys
42. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
43. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
44. Preparation of isolated rat liver cells
45. Alanine aminotransferase in clinical practice. A review
46. High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and in human plasma
47. An autopsy case of troglitazone-induced fulminant hepatitis
48. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations
49. Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents
50. Traditional pharmacological management of non-insulin-dependent diabetes
51. Hepatic dysfunction associated with troglitazone
52. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease